Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Palvella Therapeutics ( (PVLA) ) is now available.
On November 5, 2025, Palvella Therapeutics announced a new product candidate, QTORIN™ pitavastatin, designed to treat disseminated superficial actinic porokeratosis (DSAP). This announcement marks a significant step as it aims to introduce the first pathogenesis-directed therapy for DSAP, potentially impacting the company’s market position by addressing an unmet medical need for over 50,000 patients in the U.S. The development of QTORIN Pitavastatin is part of Palvella’s broader strategy to innovate in the field of rare dermatological conditions, which could enhance its standing among stakeholders and within the industry.
The most recent analyst rating on (PVLA) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing first-in-disease therapies for patients with rare skin diseases. The company is working on innovative treatments, such as QTORIN Pitavastatin, aimed at addressing conditions like disseminated superficial actinic porokeratosis (DSAP), a serious skin disease with no current FDA-approved therapies.
Average Trading Volume: 167,008
Technical Sentiment Signal: Hold
Current Market Cap: $830.1M
Learn more about PVLA stock on TipRanks’ Stock Analysis page.